Open-Label Study to Evaluate the Safety and Tolerability of Telaprevir in Combination With Sofosbuvir in Treatment Naive Subjects Chronically Infected With Hepatitis C Virus Genotype 1.
Phase of Trial: Phase II
Latest Information Update: 25 Apr 2018
Price : $35 *
At a glance
- Drugs Telaprevir (Primary) ; Sofosbuvir
- Indications Hepatitis C
- Focus Adverse reactions
- Acronyms STEADFAST
- 05 Mar 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov
- 21 May 2014 According to ClinicalTrials.gov record. status changed from recruiting to active, no longer recruiting.
- 15 Jan 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.